CD8A and neoplasm: To analyze whether the ERSGs scoring system was associated with ICB therapy, we further explored the relationship between ERSGs score and several well-known ICB response predictors, such as tumor mutation burden (TMB) (45), MSI status (46), PD-L1, CD8A, TIDE score, TIS, and COX-IS.